Coave Therapeutics lève €32 millions d'euros en série A pour accélérer le développement de ses médicaments génétiques de nouvelle génération
January 09, 2025 03:00 ET
|
Coave Therapeutics
Le tour de table a été mené par Novo Holdings A/S et Bpifrance (dans le cadre de la stratégie d'investissement InnoBio), avec la participation d'investisseurs américains et européens, Invus et UI...
Coave Therapeutics Secures €32 Million ($33 Million) in Series A Financing to Advance its Next-Generation Genetic Medicines
January 09, 2025 03:00 ET
|
Coave Therapeutics
Financing co-led by Novo Holdings A/S and Bpifrance (as part of the InnoBio investment strategy) and joined by leading US and EU investors Invus and UI Investissement alongside existing...
Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer
December 19, 2024 07:00 ET
|
Lexeo Therapeutics
Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer
Muscular Dystrophy Association and AFM-Téléthon Announce $510,000 Research Grant Awards Advancing Treatments for Mitochondrial Myopathies and ALS
December 18, 2024 08:44 ET
|
Muscular Dystrophy Association
New York, Dec. 18, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) and AFM-Téléthon (the French muscular dystrophy association) are proud to announce the awarding of two...
Muscular Dystrophy Association and Coalition to Cure Calpain 3 Partner to Fund $300,000 Research Grant for Gene Therapy Development in Limb-Girdle Muscular Dystrophy
December 17, 2024 08:54 ET
|
Muscular Dystrophy Association
New York, Dec. 17, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) and Coalition to Cure Calpain 3 (C3) announced today collaborative funding of a $300,000 research grant to...
Coave Therapeutics Receives Grant from the ALS Association to Advance its CTx-TFEB Program as a Potential Treatment for All Forms of ALS
February 29, 2024 07:00 ET
|
Coave Therapeutics
CTx-TFEB is a novel, targeted genetic medicine approach designed to promote autophagy and reduce the accumulation of toxic protein aggregates in neurons Funding aims to support the progression of...
Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency
December 06, 2023 16:08 ET
|
Wave Life Sciences USA, Inc.
Wave Life Sciences Announces Initiation of Dosing in Clinical Trial Evaluating First-Ever RNA Editing Candidate, WVE-006, in Alpha-1 Antitrypsin Deficiency
FDA approves muscular dystrophy drug built on Children’s National research
October 27, 2023 09:27 ET
|
Children's National Hospital
WASHINGTON, D.C., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Boys with Duchenne muscular dystrophy (DMD) have a clinically proven, new treatment option with the Food and Drug Administration’s approval...
Coave Therapeutics to Present at Upcoming Conferences
September 28, 2023 08:15 ET
|
Coave Therapeutics
Paris, France, September 28, 2023 – Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies for CNS (Central Nervous System) and eye diseases, announces...
Muscular Dystrophy Association Celebrates FDA Approval of Sarepta Therapeutics’ ELEVIDYS for Treatment of Duchenne Muscular Dystrophy
June 22, 2023 15:31 ET
|
Muscular Dystrophy Association
New York, June 22, 2023 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) accelerated approval of ELEVIDYS (delandistrogene...